Journal of hepatology

publication venue for

Hilar bile duct carcinoma. 1998
Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study. 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.. 81. 2024
B-cell characteristics define HCV reinfection outcome.. 81. 2024
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.. 79. 2023
A global research priority agenda to advance public health responses to fatty liver disease.. 79. 2023
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.. 78. 2022
IL6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. 2022
Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.. 77. 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.. 77. 2022
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.. 76. 2021
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.. 75. 2021
Liver-related mortality is similar among men and women with cirrhosis.. 73. 2020
Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.. 73. 2020
NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly.. 72. 2020
B cell immunodominance in primary hepatitis C virus infection.. 72. 2019
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.. 72. 2019
Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.. 69. 2018
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.. 69. 2018
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.. 67. 2017
Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.. 66. 2016
Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.. 65. 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.. 65. 2016
A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.. 63. 2015
Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.. 63. 2015
Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.. 63. 2015
Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL).. 62. 2014
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.. 61. 2014
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.. 60. 2013
Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.. 59. 2013
WITHDRAWN: Recurrence prediction of hepatocellular carcinoma after liver transplantation by ischemia time and tumor characteristics. 2013
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.. 57. 2012
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.. 55. 2011
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.. 47. 2007
Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis.. 44. 2006
Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: the transplant hepatologist.. 44. 2006
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial.. 43. 2005
Interleukin-6 release by rat liver macrophages.. 11. 1990
Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA.. 3. 1986
Antisense therapy for hepatitis C virus infection. 2013
Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC). 2025
Challenges in Applying MASLD Risk Algorithms in Pregnancy: A Call for Adaptation and Inclusion. 2025
Pre-transplant immune checkpoint inhibitor use: The intersection between medicine, surgery and pharmacy. 2024
MEFIB vs. MAST and FAST: Not a competition but useful tools. 2022
Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach? 2019
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. 2011
Loss or gain of function: The functional complexity of the PNPLA3 I148M variant.. 82. 2025
NASH cirrhosis trials and major adverse liver outcomes: Big data needed.. 78. 2022
Why are there no strategies for NAFLD?. 76. 2021
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.. 73. 2020
Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.. 64. 2015
Living donor liver transplantation for HCV: will the true outcomes stand up?. 57. 2012
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?. 55. 2011
Individualizing hepatitis B infection prophylaxis in liver transplant recipients.. 55. 2011
Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice.. 54. 2010
Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea?. 47. 2007
Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. 2014
The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials. 2025
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. 2023
Post-liver transplantation patient experience. 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. 2023
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. 2023
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. 2020
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. 2020
HCV animal models and liver disease. 2014
The gut microbiota and the liver. Pathophysiological and clinical implications. 2012
Thrombocytopenia associated with chronic liver disease. 2008

VIVO Weill Cornell Medical College

Journal of hepatology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)